<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04273516</url>
  </required_header>
  <id_info>
    <org_study_id>3498</org_study_id>
    <nct_id>NCT04273516</nct_id>
  </id_info>
  <brief_title>Rivaroxaban Plus ASA in Embolic Stroke of Undetermined Source(AREST-ESUS)</brief_title>
  <acronym>AREST-ESUS</acronym>
  <official_title>Aspirin Plus Rivaroxaban Efficacy and Safety in Embolic Stroke of Undetermined Source: A Randomized, Placebo Controlled, Outcome Assessor Blind, Feasibility Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mazandaran University of Medical Sciences</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mazandaran University of Medical Sciences</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Approximately 17% of all patients with stroke are classified as having ESUS, which is&#xD;
      associated with a considerable rate of stroke recurrence 4-5 % per year.&#xD;
&#xD;
      Despite recent scientific advances in acute ischemic stroke treatment in recent&#xD;
      decades,consensus treatment of all guidelines is still ASA&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is an outcome assessor blind, randomized, parallel, placebo-controlled pilot study on&#xD;
      ischemic stroke of undetermined source which will be conducted in Bu Ali Sina hospital in&#xD;
      Sari, Iran.&#xD;
&#xD;
      Patients with recent stroke with criteria of ESUS, will be randomized to Rivaroxaban 2.5 mg&#xD;
      BID plus ASA 80 mg daily or ASA 80 mg plus placebo (1:1 ratio) and have visit every 3 month&#xD;
      until 1 year&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 22, 2020</start_date>
  <completion_date type="Anticipated">May 2022</completion_date>
  <primary_completion_date type="Anticipated">February 2022</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Triple (Participant, Care Provider, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Rate of stroke recurrence</measure>
    <time_frame>Rate of stroke recurrence during one year fallow up</time_frame>
    <description>Number of stroke events during 1 year of study</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Rate of major bleeding</measure>
    <time_frame>During 1 year of study</time_frame>
    <description>Rate of major bleeding according to criteria of the International Society of Thrombosis and Hemostasis</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Rate of stroke or systemic embolisms</measure>
    <time_frame>During 1 year of study</time_frame>
    <description>Number of stroke or systemic embolisms recurrence during 1 year of study</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mortality rate</measure>
    <time_frame>During 1year of study</time_frame>
    <description>Number of all cause mortality during study</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of non-major bleeding</measure>
    <time_frame>During 1year of study</time_frame>
    <description>Rate of non-major bleeding according to criteria of the International Society of Thrombosis and Hemostasis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of intracranial bleeding</measure>
    <time_frame>During 1year of study</time_frame>
    <description>Rate of ICH during study</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of fatal bleeding</measure>
    <time_frame>During 1 year of study</time_frame>
    <description>Rate of fatal bleeding in any site</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Stroke</condition>
  <condition>Prevention</condition>
  <arm_group>
    <arm_group_label>Intervention</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Tablet Rivaroxaban 2.5 mg 2 times daily plus ASA 80 mg daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Comparator</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Tab ASA 80 mg daily plus placebo ( similar to rivaroxaban tablet) 2 times daily</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rivaroxaban 2.5 Mg Oral Tablet</intervention_name>
    <description>Tablet Rivaroxaban 2.5 mg 2 times daily add to standard treatment ASA 80 mg daily</description>
    <arm_group_label>Intervention</arm_group_label>
    <other_name>Axabin 2.5</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rivaroxaban placebo tablets</intervention_name>
    <description>Placebo tablets add to ASA 80 mg daily that is standard treatment</description>
    <arm_group_label>Comparator</arm_group_label>
    <other_name>Placebo</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. signing the inform consent&#xD;
&#xD;
          2. recent ischemic stroke ( 7-60) days with criteria of ESUS&#xD;
&#xD;
          3. only one risk factors of potential embolic source including:&#xD;
&#xD;
               1. PTFV1 in standard ECG ≥0.05 mm.s or ≥0.005 mv.s&#xD;
&#xD;
               2. LVH in standard ECG( Sokolow index≥ 35 mm) or on echocardiography&#xD;
&#xD;
               3. Moderate or severe valvular disorder on echocardiography (except MS)&#xD;
&#xD;
               4. PFO without indication of occlusion&#xD;
&#xD;
               5. Left atrium enlargement in echocardiography&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. History of hypersensitivity to the investigational medicinal product&#xD;
&#xD;
          2. Indication for anticoagulation&#xD;
&#xD;
          3. Indication for dual antiplatelet therapy&#xD;
&#xD;
          4. Contraindication to investigational medications&#xD;
&#xD;
          5. History of intracranial, intraocular, spinal, retroperitoneal or atraumatic&#xD;
             intra-articular bleeding&#xD;
&#xD;
          6. Gastrointestinal bleed or major surgery within 3 months&#xD;
&#xD;
          7. Planned or likely revascularization (any angioplasty or vascular surgery) within the&#xD;
             next 3 months&#xD;
&#xD;
          8. HAS-BLED score &gt;3&#xD;
&#xD;
          9. Severe non-cardiovascular comorbidity with life expectancy &lt; 3 months&#xD;
&#xD;
         10. Severe renal failure, defined as Glomerular Filtration Rate (GFR) &lt;15ml/min, Dialysis,&#xD;
             transplant, Cr &gt;2.26 mg/dL&#xD;
&#xD;
         11. Severe hepatic insufficiency, Cirrhosis or Bilirubin &gt;2x Normal or AST/ALT/AP &gt;3x&#xD;
             Normal&#xD;
&#xD;
         12. Modified Rankin Scale of &gt;=4 at time of randomization or inability to swallow&#xD;
             medications.&#xD;
&#xD;
         13. Hemorrhagic transformation of infarction detected by Brain CT or MRI at the time of&#xD;
             drug application&#xD;
&#xD;
         14. Radiological or microbiological evidence of COVID-19 infection&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Athena Sharifi-Razvi</last_name>
    <role>Principal Investigator</role>
    <affiliation>mazandaran university of medical science</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Monireh Ghazaeian</last_name>
    <role>Study Director</role>
    <affiliation>mazandaran university of medical science</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Athena Sharifi Razavi</last_name>
    <phone>00989113510136</phone>
    <email>athena.sharifi@yahoo.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Bou- Ali Sina Hospital</name>
      <address>
        <city>Sari</city>
        <state>Mazandaran</state>
        <country>Iran, Islamic Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Monireh Gazaeian</last_name>
      <email>ghazaeianm@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Neurology Centre</last_name>
      <phone>00981133343014</phone>
    </contact_backup>
  </location>
  <location_countries>
    <country>Iran, Islamic Republic of</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>February 15, 2020</study_first_submitted>
  <study_first_submitted_qc>February 15, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">February 18, 2020</study_first_posted>
  <last_update_submitted>September 19, 2021</last_update_submitted>
  <last_update_submitted_qc>September 19, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 24, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Mazandaran University of Medical Sciences</investigator_affiliation>
    <investigator_full_name>Athena Sharifi Razavi</investigator_full_name>
    <investigator_title>Assistant Professor in Neurology</investigator_title>
  </responsible_party>
  <keyword>ESUS</keyword>
  <keyword>DOACS</keyword>
  <keyword>Prevention</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stroke</mesh_term>
    <mesh_term>Embolic Stroke</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rivaroxaban</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_access_criteria>Data will be available for researchers and scientific persons after request and review the proposal .</ipd_access_criteria>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

